Jeffrey G. Smith - Concepedia

Author

Jeffrey G. Smith

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

J G Smith, J. G. Smith, J.G. Smith, J. G. Smith, JEFFREY G. SMITH, Jeffrey G Smith, Jeffrey G. Smith, Jeffrey G. Smith

Publications

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy University of Colorado Denver University of California San Diego VA San Diego Healthcare System

About

Jeffrey G. Smith is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, immunology, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	1.2K
2	Health Sciences	3	3	340
3	Allergy	3	3	121
4	Education	2	2	65
5	Engineering	1	1	29

Jeffrey G. Smith

Publications

Citations

H-Index

Page 1

	Year	Citations
Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 <i>gag</i> Gene Danilo R. Casimiro, Ling Chen, Tong‐Ming Fu, Journal of Virology	2003	396
Varicella‐Zoster Virus–Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine Myron J. Levin, Michael N. Oxman, J. H. Zhang, The Journal of Infectious Diseases	2008	346
Decline in Varicella‐Zoster Virus (VZV)–Specific Cell‐Mediated Immunity with Increasing Age and Boosting with a High‐Dose VZV Vaccine Myron J. Levin, Jeffrey G. Smith, Robin M. Kaufhold, The Journal of Infectious Diseases Healthy SubjectsImmunologyIncreasing AgeHigh‐dose Vzv VaccineImmunotherapy	2003	316
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) K Bartizal, Christopher Gill, George K. Abruzzo, Antimicrobial Agents and Chemotherapy Antifungal AgentHealth SciencesAntifungal AgentsMedicineMk-0991 Mfcs	1997	312
Varicella‐Zoster Virus–Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine Adriana Weinberg, Jane H. Zhang, Michael N. Oxman, The Journal of Infectious Diseases	2009	268
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis George K. Abruzzo, Amy Flattery, Christopher Gill, Antimicrobial Agents and Chemotherapy	1997	244
Development and Validation of a Gamma Interferon ELISPOT Assay for Quantitation of Cellular Immune Responses to Varicella-Zoster Virus Jeffrey G. Smith, Xu Liu, Robin M. Kaufhold, Clinical and Diagnostic Laboratory Immunology Laboratory ImmunologyViral DiagnosticsViral PathogenesisImmunologyImmunotherapy	2001	179
Efficacy of the Echinocandin Caspofungin against Disseminated Aspergillosis and Candidiasis in Cyclophosphamide-Induced Immunosuppressed Mice George K. Abruzzo, Charles Gill, Amy Flattery, Antimicrobial Agents and Chemotherapy	2000	170
Establishing Acceptance Criteria for Cell-Mediated-Immunity Assays Using Frozen Peripheral Blood Mononuclear Cells Stored under Optimal and Suboptimal Conditions Jeffrey G. Smith, Heather R. Joseph, Tina Green, Clinical and Vaccine Immunology	2007	93
Varicella Zoster Virus-Specific Immune Responses to a Herpes Zoster Vaccine in Elderly Recipients With Major Depression and the Impact of Antidepressant Medications Michael R. Irwin, Myron J. Levin, Mark L. Laudenslager, Clinical Infectious Diseases	2013	84

Page 1